Advertisement

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement

Jul

10

Today In Oncology

FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer

Long-Term Follow-up of Postoperative Chemoradiotherapy With 3-Weekly vs Weekly Cisplatin in Head and Neck Cancer

Novel Gene Fusion Detector for Pediatric B-ALL Shows High Sensitivity

Advanced Gastric or GEJ Cancer First-Line Disitamab Vedotin, Tislelizumab, and S-1

In the United States, Men May Be More Likely Than Women to Receive Later-Stage Diagnoses for Many Cancer Types

Advertisement

© 2026 HSP News Service, L.L.C.